FibroBiologics announced that trading of its stock began today in a direct listing on the Nasdaq under the ticker symbol FBLG. Thw reference price was set at $8 a share.
Houston-based FibroBiologics is a clinical-stage biotechnology company focused on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials.
The company intends to offer 4,806,226 shares in the listing.
A private placement was completed over a year ago at the equivalent of $6.76 per share, according to the prospectus.
FibroBiologics holds 150+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, wound healing, reversing organ involution and cancer. Read more.
